"Designing Growth Strategies is in our DNA"
The global viral clearance market size was valued at USD 539.6 million in 2022. The market is projected to grow from USD 621.1 million in 2023 to USD 1,867.5 million by 2030, exhibiting a CAGR of 17.0% during the forecast period.
Viral clearance is an important process to manufacture biologics, such as biosimilar, antibodies, stem cell products, biopharmaceuticals, and others, to ensure product safety. Manufacturers of pharmaceuticals and other products derived from animal or human tissues are required to validate the ability of their purification and manufacturing process to inactivate or remove viruses or TSE agents and ensure product safety.
The market growth of viral clearance is mainly attributed to increasing investment in pharmaceutical and biotechnology companies and increasing demand for vaccines and other biotherapeutic agents. Moreover, other factors such as increasing R&D activities due to the rising incidence and large economic burden of chronic diseases are enhancing the overall market growth. As per WHO, in 2020, the prevalence of chronic diseases was increased by 57.0%.
However, the high cost associated with the virus clearing process and the consuming process for developing the drug has been restraining the market growth. For instance, Bio-Pharm International, in December 2020, stated that demonstrating virus clearance during the downstream process is the biggest challenge as it depends on many major factors.
Supply Chain Disruptions to Hinder Market Revenues
The COVID-19 pandemic negatively affected the market in 2020. The lack of staff & workforce, risk of infection spread, and slowed manufacturing rate in the biopharmaceutical and biotech industries challenged the market. The decrease in production is attributable to supply chain disruptions, implementation of safety precautions, and logistical challenges.
However, in 2021, the market observed a sudden rise in its growth. This growth was attributed to the increase in the number of clinical trials, and the increase in demand for novel and effective vaccines for COVID-19 were the key factors responsible for the market's growth. Due to the COVID-19 outbreak, many pharmaceutical and biopharmaceutical companies boosted their R&D and manufacturing processes to develop vaccines and drugs against the SARS-CoV-2 virus. For instance, as per Regulatory Affairs Professional Society, as of January 2022, there are 34 COVID-19 vaccines approved.
Moreover, after the COVID-19 outbreak, many new partnerships and collaborations worldwide with pharmaceutical companies and academic institutes for COVID-19 vaccine research & development were recorded to develop effective drugs.
Request a Free sample to learn more about this report.
Increasing Biosimilar Approvals to Positively Impact Market Growth
Biosimilar has been experiencing a boost in its demand globally due to the varied features such as low treatment cost, easy availability, high efficiency, and others. The increase in biosimilar approval can improve patient access to care by increasing the number of medication options at considerably lower costs.
The commercialization of biosimilar began in Europe, where broad reimbursement coverage, high treatment rates, and dedicated regulatory pathways created a thriving market. As per a report by NCBI in 2020, the EMA received 65 marketing authorization applications for biosimilar medicines, and 55 biosimilars are available in the European Union market.
Biological products used for human use have to pass through viral clearance every time as it is being manufactured to remove viral contamination.
Every approved biosimilar has to pass through these clearance studies. Therefore, the increasing number of approved drugs has also increased these services’ demand, thereby aiding the viral clearance market growth.
Increasing R&D Expenditure in Pharmaceutical & Biotechnology Sectors to Boost Market Growth
Most pharmaceutical and biopharmaceutical businesses continue to put significant resources into developing new medications and technologies.
The pharmaceutical business, in particular, is heavily investing in research and development. Pharmaceutical firms engage in research and development initiatives to bring high-quality, innovative goods to market.
The development and manufacturing of new biopharmaceuticals require to go through virus safety procedures. Therefore, the increasing number of R&D for new biological products has increased the demand for these services.
Increasing Regulations on Viral Safety to Spike Industry Development
Viral safety and its evaluation are significant steps for product safety. Regulatory bodies strongly focus on viral safety and expect high-quality data to support it, especially for IND and BLA approvals. Familiarity with the process and regulatory requirements and expertise in the key areas of these processes are important for strategic planning and can yield savings in time, effort, and money.
Regulations on viral safety of pharmaceutical products have evolved over decades to decrease the risk of transmitting viruses.
Such regulations on viral safety during pharmaceutical product development have increased the need for the services to conduct studies more effectively.
High Costs Associated with Novel Technologies of Viral Clearance to Limit Market Growth
The high cost associated with technologies used for virus clearing have restricted the global growth of the market.
Furthermore, the viral clearance service providers confront issues in attracting and maintaining highly competent experts as they compete for qualified and experienced scientists with pharmaceutical, biotechnology, medical device businesses, and academic and research institutions. Companies must give higher compensations and other incentives to compete effectively, impacting players' finances and operational outcomes, particularly small-scale analytical testing providers. This scarcity of qualified specialists could hinder the adoption of new technologies and procedures, limiting the market growth in the coming years.
Hence, rising cost of these processes is expected to limit the industry’s progress in the coming years.
To know how our report can help streamline your business, Speak to Analyst
Viral Removal Segment to Dominate Owing to its High Efficiency
Based on method, the market of viral clearance is classified into viral removal method, viral inactivation method, and viral detection method.
The viral removal method segment held the major share in 2022. This segment may experience strong growth due to the method's efficiency, flexibility, and many advantages.
The viral inactivation method segment is anticipated to exhibit strong growth. This growth is attributable to the increasing number of new vaccines and therapeutics approval and demand for new products such as plasma proteins and gene therapy products.
Furthermore, the viral detection method segment is expected to grow at a considerable CAGR. Viral detection is an important step in the viral clearing process as this step determines how virus removal or inactivation can be used. This factor has been boosting the growth of the viral removal segment.
Increasing Manufacture of Vaccines to contribute to the Growth of Vaccines Segment
Based on application, the market is segmented into vaccines, blood & blood products, recombinant proteins, cellular & gene therapy products, and others.
The vaccines segment is anticipated to hold the largest shares of the market by the end of the forecast period due to the rise in demand for COVID-19 vaccines, immunization against chronic diseases polio, hepatitis, cervical cancer, and others.
The blood & blood products segment is anticipated to expand substantially during the upcoming years. The cardiology segment is expected to grow due to the strong demand for blood transfusion and therapeutics derived from blood components.
Cellular & gene therapy products are expected to grow at the highest CAGR during the forecast period due to increasing use of cellular therapies in treating various disorders, increasing public and private funding for stem cell research, rising awareness about stem cell therapies, and the use of tissue-based therapies to treat various diseases.
High Procedural Volume in Clinics & Hospital to Propel Segmental Growth
Based on end-user, the market is segmented into pharmaceutical and biotech industry, academic research institutes, CROs, and others.
The pharmaceutical and biotech industry segment accounted for the highest viral clearance market share in 2022 and is expected to expand at a significant CAGR during the forecast period. This segment’s high growth rate is attributed to the mandatory requirement for virus removal or inactivation during the development of biopharmaceutical and other biological products by regulatory bodies.
The CROs segment is anticipated to expand at the substantial CAGR during the forecast period, 2023-2030. The growth rate is attributed to the pharmaceutical companies' increased outsourcing of early-phase development services and clinical and laboratory testing services.
The academic and research institutes segment is expected to grow at the highest CAGR during the forecast period. The growing number of research and study on new drug development by research institutes in the region is anticipated to accelerate the segment's growth globally.
North America Viral Clearance Market Size, 2022 (USD million)
To get more information on the regional analysis of this market, Request a Free sample
The market in North America reached USD 201.9 million in 2022 and is anticipated to grow strongly in the forthcoming years. The presence of national institutes supporting biotechnology and life science research, growth in the pharmaceuticals industry, and the increasing number of drug approvals across the region are expected to drive market growth.
Europe is expected to experience the second-highest growth in the market on account of the strong foundation of biotechnology in the European countries such as France and Germany and an increase in the amount of research and development initiatives by biotechnological companies in the region.
Simultaneously, Asia Pacific may expand during the upcoming years. This growth is attributed to the increase in generics development and manufacturing, surge in funding for medical research, and a large number of CROs in the region.
The Latin American and the Middle East and Africa regions may witness slow growth because of rising healthcare expenditures and increasing demand for biopharmaceuticals.
Players with Strong and Diverse Product Portfolio to Dominate Market Position
Based on the competitive landscape, prominent market players such as Merck KGaA, Charles River, Wuxi Biologics, and Kedrion account for a major market share. These companies focus on several strategies such as continuous R&D, mergers, acquisitions, and product portfolio expansion resulting in strong regulatory approvals.
Other key players, such as Texcell, Vironova, and Sartorius AG, had substantial market shares in 2022.
KEY INDUSTRY DEVELOPMENTS:
To gain extensive insights into the market, Request for Customization
The global viral clearance market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, product type, and application. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the market's growth in recent years.
CAGR of 17.0% from 2023-2030
Value (USD million)
By Method, Application, End-user, and Region
Fortune Business Insights says that the global market stood at USD 539.6 million in 2022 and is projected to reach USD 1,867.5 million by 2030.
The market is expected to exhibit steady growth at a CAGR of 17.0% during the forecast period (2023-2030).
By method, the viral removal method segment is set to lead the market.
Increasing investment in pharmaceutical and biotechnology industries and rising demand for vaccines and other biotherapeutic agents are expected to drive the market growth.
Merck KGaA, Charles River, Wuxi Biologics, Sartorius AG, and Kedrion are the top players in the market.
North America is expected to hold the highest market share.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry